SPEVIGO^®(spesolimab)PFIZERHK Reg. No. HK-68915 (03 Dec, 2025)

Composition:²

For subcutaneous use:

• Injection: 150 mg/mL in a single-dose prefilled syringe

Indication:²

SPEVIGO^® is an interleukin-36 receptor antagonist indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg

References

2. FDA. Highlights of Prescribing Information. March 2024. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761244s003lbl.pdf.  [Accessed 23 December 2025].